As we approach the heath insurance payers, what questions should we ask about their business policies to support further adoption of clinical genomics? Here is my initial list. Please provide your feedback below, and together, let’s help solve these coverage and pre-authorization issues.
Do you have suggestions or feedback regarding this Call to Action? What steps or solutions do you suggest to meet these goals? Have you taken action and has it resulted in a particular outcome? Provide your comments using the form below or feel free to send an email directly to firstname.lastname@example.org.
I will use the feedback provided to create additional posts around this topic which you will be able to view on this page. Please note that no identifying information will be included in anything posted on this website unless such identification is consented.
The current lack of an ID for each unique genetic test raises the possibility of confusion among clinicians ordering tests and laboratories reporting them. This
The adoption of clinical genomics as standard of care has been slow. In this blog post, we will examine the major issues affecting clinical adoption